ARS Pharmaceuticals (SPRY) Non-Current Debt (2021 - 2026)

ARS Pharmaceuticals (SPRY) posted Non-Current Debt of $96.5 million for Q1 2026, little changed sequentially from $96.4 million in Q4 2025.

ARS Pharmaceuticals (SPRY) Non-Current Debt (2021 - 2026) Analysis & Trends

ARS Pharmaceuticals has reported Non-Current Debt for 3 years, with the latest figure at $96.5 million in Q1 2026.

Quarterly Non-Current Debt changed N/A year-over-year to $96.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $96.5 million (changed N/A YoY) and the FY2025 annual result came in at $96.4 million, changed N/A from the prior year.
Non-Current Debt held at $96.5 million in Q1 2026 per SPRY's latest filing, from $96.4 million in the prior quarter.
Over five years, Non-Current Debt peaked at $96.5 million in Q1 2026 and troughed at $96.2 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	882.16 Mn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	8.96 Bn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	546.77 Mn
10	ARS Pharmaceuticals	561.88 Mn	418.03 Mn	-	96.68 Mn

Download Data